2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasm, Residual
3
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Neoplasms
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lung Neoplasms
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Colorectal Neoplasms
2
Uterine Cervical Neoplasms
1
Smoldering Multiple Myeloma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms, Plasma Cell
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Plasma Cell
1
Interventions
Filgrastim
20
Etoposide
20
Ifosfamide
19
Cyclophosphamide
18
Vincristine
13
Radiotherapy
13
Doxorubicin
13
Peripheral Blood Stem Cell Transplantation
12
Melphalan
12
Carboplatin
10
Busulfan
9
Topotecan
8
Temozolomide
8
Magnetic Resonance Spectroscopy
8
X-Rays
6
Thiotepa
6
Phantoms, Imaging
6
Irinotecan
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
trioctyl phosphine oxide
4
Mesna
4
Docetaxel
4
Dactinomycin
4
temsirolimus
3
etoposide phosphate
3
cixutumumab
3
Neoadjuvant Therapy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Maintenance
×
Clear all
NCT03011528
2025-11-21
CombinaiR3
Institut Curie
Phase 2
Completed
45 enrolled